Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 11 Jun 2012 Primary endpoints added as reported by ClinicalTrials.gov.